多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述

State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.

CAR-T 与 CAR NK 细胞的在靶脱瘤效应差异提示细胞治疗的疗效与安全性不同

Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies.

烟酰胺扩增的 CD38 缺失、表达增强型 CD38 嵌合抗原受体的同种异体 NK 细胞靶向多发性骨髓瘤细胞

Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myelo

表达亲和力优化 CD38 嵌合抗原受体的 CD38 敲除 NK 细胞成功靶向急性髓系白血病并减少效应细胞自相残杀

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with red

αCD38 嵌合抗原受体（CAR）表达自然杀伤（NK）细胞免疫治疗多发性骨髓瘤的挑战：利用细胞因子刺激 NK 细胞的 CD38dim 表型作为防止自相残杀的策略

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38di

我们的结果强调，将功能性 CD38-CAR 构建体纳入合适的 NK 细胞扩增与激活方案，可形成一种强效且可行的免疫治疗策略，用于治疗 MM 患者。

CD38-CAR 人 NK 细胞联合 ATRA 增强对表达 CD38 的血液系统恶性肿瘤的细胞毒性

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies.

释放 CAR-NK 细胞的潜力：针对 CD38 阳性恶性肿瘤的有前景的现货型治疗策略

Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies.

体外研究结果表明，抗 CD38 CAR-NK 细胞有潜力作为针对 CD38 阳性恶性肿瘤的现货型治疗策略。